Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 10
Submit an article Journal homepage
1,593
Views
10
CrossRef citations to date
0
Altmetric
Respiratory

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

Manjusha HurryNovartis Pharmaceuticals Canada Inc, Health Policy and Patient Access, Dorval, Quebec, Canada; Correspondence[email protected]
,
Zheng-Yi ZhouAnalysis Group, Health Economics and Outcomes Research, New York, NY, USA;
,
Jie ZhangNovartis Pharmaceuticals Corporation, Global Oncology Market Access & Policy, East Hanover, NJ, USA;
,
Chenxue ZhangAnalysis Group, Health Economics and Outcomes Research, Boston, MA, USA;
,
Liangyi FanAnalysis Group, Health Economics and Outcomes Research, Boston, MA, USA;
,
Mayvis RebeiraUniversity of Toronto, Canadian Center for Health Economics, Toronto, Ontario, Canada
&
Jipan XieAnalysis Group, Health Economics and Outcomes Research, New York, NY, USA;
show all
Pages 936-944 | Received 07 Mar 2016, Accepted 04 May 2016, Published online: 25 May 2016

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Alain Vergnenègre & Christos Chouaïd. (2018) Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC). Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 519-528.
Read now
Zheng-Yi Zhou, Alex Mutebi, Simeng Han, Arielle G. Bensimon, Marie Louise Ricculli, Jipan Xie, Anand Dalal & Ken Culver. (2018) Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. Journal of Medical Economics 21:6, pages 577-586.
Read now
J. J. Carlson, W. Canestaro, A. Ravelo & W. Wong. (2017) The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. Journal of Medical Economics 20:7, pages 671-677.
Read now

Articles from other publishers (7)

Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous & William W. L. Wong. (2023) A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). PharmacoEconomics 41:8, pages 945-980.
Crossref
Xudong Zhang, Pingping Fang, Guangquan Su, Shuangying Gui & Aizong Shen. (2022) Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China. Journal of Comparative Effectiveness Research 11:12, pages 871-878.
Crossref
Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie & Meaghan Gibbs. (2020) Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Ye Peng, Fang Ma, Chongqing Tan, Xiaomin Wan, Lidan Yi, Liubao Peng & Xiaohui Zeng. (2019) Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Advances in Therapy 36:11, pages 3047-3058.
Crossref
C. Chouaid & A. Vergnenègre. (2018) Les coûts du cancer du poumon. Revue des Maladies Respiratoires Actualités 10:3, pages 192-197.
Crossref
Hamzeh Albaba, Charles Lim & Natasha B. Leighl. (2017) Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. PharmacoEconomics 35:12, pages 1195-1209.
Crossref
Mengjia Qian, Bijun Zhu, Xiangdong Wang & Michael Liebman. (2017) Drug resistance in ALK-positiveNon-small cell lungcancer patients. Seminars in Cell & Developmental Biology 64, pages 150-157.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.